CompletedPhase 3NCT03079063
Study Comparing the Pharmacokinetic of Biosimilar Eptacog Alfa With Novoseven®, in Patients With Congenital Factor VII Deficiency
Studying Congenital factor VII deficiency
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- AryoGen Pharmed Co.
- Principal Investigator
- Massimo Iacobelli, MD
- Intervention
- Eptacog alfa, biosimilar(biological)
- Enrollment
- 24 enrolled
- Eligibility
- 12-65 years · All sexes
- Timeline
- 2017 – 2021
Study locations (2)
- Hemophilia Center - Hematology & Oncology Dept. Shiraz University of Medical Science, Shiraz, Iran
- Comprehensive Hemophilia Care Center, Tehran, Iran
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03079063 on ClinicalTrials.govOther trials for Congenital factor VII deficiency
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE2NCT07347249A Clinical Study to Assess Sutacimig in Participants With Congenital Factor VII DeficiencyHemab ApS
- RECRUITINGPHASE1NCT06349473A Study of Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of SR604 in Two Participants Groups (Part A: Healthy Participants, and Part B: Participants With Hemophilia A or Hemophilia B or Factor VII Deficiency)Equilibra Bioscience LLC